Estée Lauder
No proof required
Up to $5,000
Claims opening soon
S
Sun Pharmaceutical Industries and Ranbaxy Inc.
A $145 million settlement resolves claims of price fixing for generic Nexium, Diovan, and Valcyte.
ClosedSelected statesClaim status: Closed on October 11, 2022Payout: TBDNo longer claimable
About this settlement
Alleged price fixing of generic and branded versions of Nexium, Diovan, and Valcyte affecting third-party payors across the U.S. and specified states.
This settlement resolves claims that Sun Pharmaceutical Industries and Ranbaxy Inc. conspired to fix prices on generic Nexium, Diovan, and Valcyte products sold nationwide and in certain states between 2012 and 2020.
Who qualifies
- Third-party payors who purchased or paid for AB-rated generic Nexium in the U.S. or specified states between May 27, 2014 and Feb 1, 2019.
- Third-party payors who purchased or paid for Diovan or AB-rated generic versions in the U.S. or specified states between Sept 28, 2012 and April 1, 2020.
- Third-party payors who purchased or paid for Valcyte or AB-rated generic versions in the U.S. or specified states between Aug 1, 2014 and April 1, 2020.
TBD
Claim status: Closed on October 11, 2022
Audible
No proof required
Compensation pending
Claims opening soon
Government of Canada
Proof required
Up to $200,000
644 days left
Meta (Facebook)
No proof required
Up to $90
Claims opening soon
Ticketmaster
No proof required
Compensation pending
Claims opening soon
Apple
No proof required
Up to $100
Claims opening soon